The Agency for Health Care Policy and Research last week announcedplans to evaluate the safety and clinical value of FDG-PET fordiagnosing and managing epilepsy. The review will center on the use of FDG-PET to locate thefocus of epileptic seizures for
The Agency for Health Care Policy and Research last week announcedplans to evaluate the safety and clinical value of FDG-PET fordiagnosing and managing epilepsy.
The review will center on the use of FDG-PET to locate thefocus of epileptic seizures for possible surgical excision. Radiologistsat the University of California at Los Angeles and elsewhere havereported good results with this application since at least 1993.
The evaluation was requested by the Health Care Financing Administrationand will influence whether Medicare coverage will be extendedfor the procedure.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.